Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer
- PMID: 24146212
- PMCID: PMC3825490
- DOI: 10.1007/s10549-013-2731-7
Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer
Abstract
The pituitary hormone prolactin (PRL) has been implicated in tumourigenesis. Expression of PRL and its receptor (PRLR) was reported in human breast epithelium and breast cancer cells. It was suggested that PRL may act as an autocrine/paracrine growth factor. Here, we addressed the role of locally synthesised PRL in breast cancer. We analysed the expression of PRL in human breast cancer tumours using qPCR analysis and in situ hybridization (ISH). PRL mRNA expression was very low or undetectable in the majority of samples in three cDNA arrays representing samples from 144 breast cancer patients and in 13 of 14 breast cancer cell lines when analysed by qPCR. In accordance, PRL expression did not reach detectable levels in any of the 19 human breast carcinomas or 5 cell lines, which were analysed using a validated ISH protocol. Two T47D-derived breast cancer cell lines were stably transfected with PRL-expressing constructs. Conditioned medium from the T47D/PRL clones promoted proliferation of lactogen-dependent Nb2 cells and control T47D cells. Surprisingly, the PRL-producing clones themselves displayed a lower proliferation rate as compared to the control cells. Their PRLR protein level was reduced and the cells were no longer responsive to exogenous recombinant PRL. Taken together, these data strongly indicate that autocrine PRL signalling is unlikely to be a general mechanism promoting tumour growth in breast cancer patients.
Figures




Similar articles
-
Alpha2-adrenoceptor agonists trigger prolactin signaling in breast cancer cells.Cell Signal. 2017 Jun;34:76-85. doi: 10.1016/j.cellsig.2017.03.003. Epub 2017 Mar 14. Cell Signal. 2017. PMID: 28302567
-
Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.Eur J Surg Oncol. 2000 Sep;26(6):540-7. doi: 10.1053/ejso.2000.0943. Eur J Surg Oncol. 2000. PMID: 11034803
-
Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.Front Endocrinol (Lausanne). 2022 Sep 15;13:949396. doi: 10.3389/fendo.2022.949396. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36187116 Free PMC article. Review.
-
Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.FASEB J. 2018 Sep;32(9):4791-4797. doi: 10.1096/fj.201701111RR. Epub 2018 Mar 29. FASEB J. 2018. PMID: 29596024
-
Prolactin involvement in breast cancer.Endocr Relat Cancer. 1999 Sep;6(3):389-404. doi: 10.1677/erc.0.0060389. Endocr Relat Cancer. 1999. PMID: 10516853 Review.
Cited by
-
The role of Prolactin/Prolactin Receptor polymorphisms and expression in breast cancer susceptibility and outcome.Transl Cancer Res. 2020 Oct;9(10):6344-6353. doi: 10.21037/tcr-20-1120. Transl Cancer Res. 2020. PMID: 35117242 Free PMC article.
-
A novel clinically relevant antagonistic interplay between prolactin and oncogenic YAP-CCN2 pathways as a differentiation therapeutic target in breast cancer.Cell Death Dis. 2025 Mar 29;16(1):221. doi: 10.1038/s41419-025-07547-7. Cell Death Dis. 2025. PMID: 40157909 Free PMC article.
-
Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer.Front Endocrinol (Lausanne). 2022 Sep 8;13:993570. doi: 10.3389/fendo.2022.993570. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36157462 Free PMC article. Review.
-
Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis.Oncogenesis. 2021 Jan 14;10(1):10. doi: 10.1038/s41389-020-00297-5. Oncogenesis. 2021. PMID: 33446633 Free PMC article.
-
Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study.BMC Cancer. 2020 Aug 24;20(1):804. doi: 10.1186/s12885-020-07320-3. BMC Cancer. 2020. PMID: 32831062 Free PMC article.
References
-
- Swaminathan G, Varghese B, Thangavel C, Carbone CJ, Plotnikov A, Kumar KG, Jablonski EM, Clevenger CV, Goffin V, Deng L, Frank SJ, Fuchs SY. Prolactin stimulates ubiquitination, initial internalization, and degradation of its receptor via catalytic activation of Janus kinase 2. J Endocrinol. 2008;196:R1–R7. doi: 10.1677/JOE-07-0554. - DOI - PubMed
-
- Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res. 1999;5:3583–3593. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical